Brandt, SD; Tearavarich, R; Dempster, N; Cozzi, NV; Daley, PF. Synthesis and characterization of 5-methoxy-2-methyl-N,N-dialkylated tryptamines Drug Test. Anal., 1 Jan 2012, 4 (1), 24–32. 506 kB. https://doi.org/10.1002/dta.398 #5 MS,NMR
Brandt, SD; Kavanagh, PV; Dowling, G; Talbot, B; Westphal, F; Meyer, MR; Maurer, HH; Halberstadt, AL. Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives Drug Test. Anal., 1 Jan 2017, 9 (1), 115-126. 1.3 MB. https://doi.org/10.1002/dta.1974
Meyer, MR; Caspar, A; Brandt, SD; Maurer, HH. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches Anal. Bioanal. Chem., 1 Jan 2014, 406 (1), 225–237. 457 kB. https://doi.org/10.1007/s00216-013-7425-9 #5-MeO-2-Me-DALT LC,MS
Caspar, AT; Gaab, JB; Michely, JA; Brandt, SD; Meyer, MR; Maurer, HH. Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC–MS, LC–MSn, and LC-HR-MSMS Drug Test. Anal., 1 Jan 2018, 10 (1), 184–195. 546 kB. https://doi.org/10.1002/dta.2197 #D1
Klein, LM; Cozzi, NV; Daley, PF; Brandt, SD; Halberstadt, AL. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs Neuropharmacology, 1 Nov 2018, 142, 231-239. 753 kB. https://doi.org/10.1016/j.neuropharm.2018.02.028